From accessing medicines to intellectual property to drug safety, PhRMA is devoted to advancing public policies that support innovative medical research, improve treatments and yield real results.
Today, PhRMA CEO John J. Castellani sent the following statement for the record to the Energy and Commerce Health Subcommittee on the hearing they’re holding on the 340B program:
Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004
Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
"1. Information Collection."